Angion Biomedica Corp. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Angion Biomedica Corp. | ANGN - NASDAQ |
$14.00-$16.00 | $16.00 | $17.62 | 5 million | 2/5/2021 |
| Cowen, Stifel | ||||||
Co-Manager(s): HC Wainwright, Oppenheimer | ||||||
| Health Care | ||||||
Filing(s): 1st Filed 2014-04-15 Terms Added 2014-05-24 Filed 2021-01-15 Terms Added 2021-02-01 | ||||||
Angion Biomedica Corp. Quote & Chart - Click for current quote - ANGN
IPO Boutique aggregates information on public companies and private companies, such as Angion Biomedica Corp. "ANGN" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Angion Biomedica Corp. (adapted from Angion Biomedica Corp. prospectus):
They are a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases.
This description is adapted from Angion Biomedica Corp. prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases.
This description is adapted from Angion Biomedica Corp. prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as Angion Biomedica Corp. "ANGN" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.